This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GSK159802
Description: 159802 is an inhaled long-acting (once-daily) Beta2 agonist (LABA). This type of drug relaxes smooth muscles in the airways, leading to airway dilation and increased air flow.
Deal Structure: 159802 is a compound in the Beyond Advair collaboration between Theravance and GlaxoSmithKline (GSK), started in November 2002. The purpose is to develop once-daily long-acting beta2 agonists (LABAs) for the treatment of asthma and COPD. (Beyond Advair refers to a goal of replacing GSK's Advair, and inhaled twice-a-day combination LABA and inhaled corticosteroid [ICS].)
Each company contributed four LABA product candidates, which were pooled for development and eventual commercialization. A joint steering committee was formed to optimize the development of the compounds and their time to market. GSK has the responsibility to develop and commercialize one or more of the pooled compounds for use as a single agent and/or in combination medicines, utilizing GSK's proprietary drug delivery technology. GSK has exclusive, worldwide manufacturing and commercialization rights.
In connection with this collaboration, in 2002, Theravance received from GSK an upfront payment of $10 million...See full deal structure in Biomedtracker
Partners: Innoviva, Inc.
Additional information available to subscribers only: